Earnings Summary

Intercept Pharmaceuticals, Inc.’s revenue jumped 16.67% since last year same period to $83.72Mn in the Q2 2023. On a quarterly growth basis, Intercept Pharmaceuticals, Inc. has generated 23.19% jump in its revenue since last 3-months.

Intercept Pharmaceuticals, Inc.’s net profit jumped 22.13% since last year same period to $-5.86Mn in the Q2 2023. On a quarterly growth basis, Intercept Pharmaceuticals, Inc. has generated 81.76% jump in its net profits since last 3-months.

Intercept Pharmaceuticals, Inc.’s net profit margin jumped 33.26% since last year same period to -7% in the Q2 2023. On a quarterly growth basis, Intercept Pharmaceuticals, Inc. has generated 85.19% jump in its net profit margins since last 3-months.

Intercept Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.39 - a -108.46% fall from last quarter’s estimates.

Intercept Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.39.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Intercept Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Intercept Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.